2021 CMSC Annual Meeting

Tag: NYU Langone Health

Poster-Quality of Life and Outcomes

A Real-World Study Characterizing Symptoms and Impacts of Fatigue in US Adults with Relapsing Multiple Sclerosis Using a Novel Disease Specific Scale

Background: Fatigue is among the most frequent and disabling symptoms in RMS patients. Objectives: To measure multiple sclerosis (MS)...

Read More

Poster-Disease-modifying Therapy

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More

Poster-Disease-modifying Therapy

Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...

Read More